In June 2022, the FDA granted accelerated approval to the combination of dabrafenib and trametinib for unresectable or metastatic solid tumors with BRAF V600E mutation, establishing BRAF V600E as a pan-tumor biomarker. The gene discussed is BRAF; the disease is neoplasm.